SE506529C2 - Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori - Google Patents

Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori

Info

Publication number: SE506529C2
Authority: SE; Sweden
Prior art keywords: thiocyanate; lactoperoxidase; preparation; peroxide; peroxide donor
Prior art date: 1996-01-23

Application number

SE9600233A

Other languages

English (en)

Swedish (sv)

Other versions

SE9600233L (sv

SE9600233D0 (sv

Inventor

Carl Olof Claesson

Gustaf Lindewald

Original Assignee

Semper Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-01-23

Filing date

1996-01-23

Publication date

1997-12-22

1996-01-23 Application filed by Semper Ab filed Critical Semper Ab

1996-01-23 Priority to SE9600233A priority Critical patent/SE506529C2/sv

1996-01-23 Publication of SE9600233D0 publication Critical patent/SE9600233D0/xx

1997-01-22 Priority to AU15627/97A priority patent/AU731221B2/en

1997-01-22 Priority to US09/117,029 priority patent/US6149908A/en

1997-01-22 Priority to DE69714083T priority patent/DE69714083T2/de

1997-01-22 Priority to PCT/SE1997/000098 priority patent/WO1997026908A1/en

1997-01-22 Priority to JP9526782A priority patent/JP2000509367A/ja

1997-01-22 Priority to EP97901880A priority patent/EP1007086B1/en

1997-01-22 Priority to CA002243708A priority patent/CA2243708C/en

1997-01-22 Priority to AT97901880T priority patent/ATE220556T1/de

1997-07-24 Publication of SE9600233L publication Critical patent/SE9600233L/xx

1997-12-22 Publication of SE506529C2 publication Critical patent/SE506529C2/sv

Links

108010023244 Lactoperoxidase Proteins 0.000 title claims abstract description 19
102000045576 Lactoperoxidases Human genes 0.000 title claims abstract description 19
229940057428 lactoperoxidase Drugs 0.000 title claims abstract description 19
238000002360 preparation method Methods 0.000 title claims abstract description 12
241000590002 Helicobacter pylori Species 0.000 title abstract 2
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
229940037467 helicobacter pylori Drugs 0.000 title 1
150000002978 peroxides Chemical class 0.000 claims abstract description 21
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims abstract description 14
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims abstract description 14
230000000844 anti-bacterial effect Effects 0.000 claims abstract description 11
208000015181 infectious disease Diseases 0.000 claims abstract description 9
210000002784 stomach Anatomy 0.000 claims abstract description 4
238000001727 in vivo Methods 0.000 claims abstract 2
230000000069 prophylactic effect Effects 0.000 claims abstract 2
230000001225 therapeutic effect Effects 0.000 claims abstract 2
241000894006 Bacteria Species 0.000 claims description 12
239000004366 Glucose oxidase Substances 0.000 claims description 7
229940116332 glucose oxidase Drugs 0.000 claims description 7
108010015776 Glucose oxidase Proteins 0.000 claims description 6
239000008103 glucose Substances 0.000 claims description 6
235000019420 glucose oxidase Nutrition 0.000 claims description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
239000000825 pharmaceutical preparation Substances 0.000 claims description 5
241000186660 Lactobacillus Species 0.000 claims description 3
241000209140 Triticum Species 0.000 claims description 3
235000021307 Triticum Nutrition 0.000 claims description 3
235000013305 food Nutrition 0.000 claims description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
235000014048 cultured milk product Nutrition 0.000 claims 1
235000013365 dairy product Nutrition 0.000 claims 1
102000010445 Lactoferrin Human genes 0.000 abstract 1
108010063045 Lactoferrin Proteins 0.000 abstract 1
CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 abstract 1
229940078795 lactoferrin Drugs 0.000 abstract 1
235000021242 lactoferrin Nutrition 0.000 abstract 1
239000008187 granular material Substances 0.000 description 12
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
239000008101 lactose Substances 0.000 description 8
VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 8
235000019359 magnesium stearate Nutrition 0.000 description 5
239000000843 powder Substances 0.000 description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
VTIIJXUACCWYHX-UHFFFAOYSA-L disodium;carboxylatooxy carbonate Chemical compound [Na+].[Na+].[O-]C(=O)OOC([O-])=O VTIIJXUACCWYHX-UHFFFAOYSA-L 0.000 description 4
210000004051 gastric juice Anatomy 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
229940045872 sodium percarbonate Drugs 0.000 description 4
239000007787 solid Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
235000013336 milk Nutrition 0.000 description 3
239000008267 milk Substances 0.000 description 3
210000004080 milk Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
229920000945 Amylopectin Polymers 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
208000007882 Gastritis Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
208000025865 Ulcer Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
229960003022 amoxicillin Drugs 0.000 description 2
LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003925 fat Substances 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
238000000034 method Methods 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
-1 sorbtol Chemical compound 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
231100000397 ulcer Toxicity 0.000 description 2
AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 2
XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
240000007124 Brassica oleracea Species 0.000 description 1
235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
241000219193 Brassicaceae Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
SPAGIJMPHSUYSE-UHFFFAOYSA-N Magnesium peroxide Chemical compound [Mg+2].[O-][O-] SPAGIJMPHSUYSE-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000003831 antifriction material Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000010009 beating Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
238000005422 blasting Methods 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
108010033929 calcium caseinate Proteins 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
230000035876 healing Effects 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940039696 lactobacillus Drugs 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960004995 magnesium peroxide Drugs 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
229960000282 metronidazole Drugs 0.000 description 1
229960000381 omeprazole Drugs 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229940126409 proton pump inhibitor Drugs 0.000 description 1
239000000612 proton pump inhibitor Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000000725 suspension Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
- C12Y101/03004—Glucose oxidase (1.1.3.4)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Dairy Products (AREA)
Confectionery (AREA)
Medicinal Preparation (AREA)

SE9600233A 1996-01-23 1996-01-23 Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori SE506529C2 (sv)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
SE9600233A SE506529C2 (sv)	1996-01-23	1996-01-23	Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
AT97901880T ATE220556T1 (de)	1996-01-23	1997-01-22	Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
PCT/SE1997/000098 WO1997026908A1 (en)	1996-01-23	1997-01-22	Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
US09/117,029 US6149908A (en)	1996-01-23	1997-01-22	Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating Helicobacter pylori infection
DE69714083T DE69714083T2 (de)	1996-01-23	1997-01-22	Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
AU15627/97A AU731221B2 (en)	1996-01-23	1997-01-22	Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
JP9526782A JP2000509367A (ja)	1996-01-23	1997-01-22	ヘリコバクタピロリ感染の治療用医薬を製造するためのラクトペルオキシダーゼ、ペルオキシドドナーおよびチオシアネートの使用
EP97901880A EP1007086B1 (en)	1996-01-23	1997-01-22	Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
CA002243708A CA2243708C (en)	1996-01-23	1997-01-22	Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9600233A SE506529C2 (sv)	1996-01-23	1996-01-23	Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori

Publications (3)

Publication Number	Publication Date
SE9600233D0 SE9600233D0 (sv)	1996-01-23
SE9600233L SE9600233L (sv)	1997-07-24
SE506529C2 true SE506529C2 (sv)	1997-12-22

Family

ID=20401114

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9600233A SE506529C2 (sv)	1996-01-23	1996-01-23	Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori

Country Status (9)

Country	Link
US (1)	US6149908A (ja)
EP (1)	EP1007086B1 (ja)
JP (1)	JP2000509367A (ja)
AT (1)	ATE220556T1 (ja)
AU (1)	AU731221B2 (ja)
CA (1)	CA2243708C (ja)
DE (1)	DE69714083T2 (ja)
SE (1)	SE506529C2 (ja)
WO (1)	WO1997026908A1 (ja)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19710068A1 (de) *	1997-03-12	1998-09-17	Kramer Axel	Mittel zur Förderung der Mundhygiene und der Mundgesundheit
US5972355A (en) *	1997-09-30	1999-10-26	E-L Management Corp.	Stable compositions containing biologically active components
CA2309500C (en)	1997-11-05	2012-04-17	Koppert B.V.	Pesticide against plant-pathogenic micro-organisms
US6190667B1 (en)	1998-06-30	2001-02-20	Institut Pasteur	Methods of inhibiting Helicobacter pylori
US6399570B1 (en) *	1999-02-05	2002-06-04	Agennix, Inc.	Antimicrobial/endotoxin neutralizing polypeptide
WO2000054792A1 (en) *	1999-03-17	2000-09-21	Morinaga & Co., Ltd.	Drugs, foods, drinks and feeds containing cocoa component
US6342528B1 (en) *	2000-01-18	2002-01-29	Lynntech, Inc.	Control of microbial populations in the gastrointestinal tract of animals
WO2002015722A2 (en) *	2000-08-21	2002-02-28	Fahey Jed W	Treatment of helicobacter with isothiocyanates
WO2002069958A1 (de) *	2001-03-01	2002-09-12	Wolfgang Weuffen	Thiocyanationen zur vorbeugung und therapie von bse und ähnlichen erkrankungen beim tier und menschen
US7770577B2 (en)	2001-05-15	2010-08-10	Gregory E Conner	Methods and devices for treating lung dysfunction
US6702998B2 (en) *	2001-05-15	2004-03-09	Gregory E. Conner	Methods and devices for treating lung dysfunction
SE0200876L (sv) *	2002-03-22	2003-09-23	Krister Tano	Nässpray mot öroninflammationer
CA2489208C (en)	2003-02-24	2012-11-06	Morinaga Milk Industry Co., Ltd.	Interleukin-6 suppressive agent
WO2005018701A1 (en) *	2003-08-25	2005-03-03	Kane Biotech Inc.	Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
CN100480378C (zh)	2004-02-17	2009-04-22	森永乳业株式会社	生产乳过氧化物酶的方法
US20060289354A1 (en) *	2005-06-15	2006-12-28	Buckman Laboratories International, Inc.	Method and composition to control the growth of microorganisms in aqueous systems and on substrates
US20070092502A1 (en) *	2005-09-01	2007-04-26	Allergan, Inc.	Method of Treating Glaucoma
CA2637833A1 (en) *	2006-01-20	2007-07-26	Morinaga Milk Industry Co., Ltd	Pharmaceutical composition, food or drink, or feed for intestinal disease
US20070197388A1 (en) *	2006-02-22	2007-08-23	Buckman Laboratories International, Inc.	Haloperoxidase treatment to control algae
CN106139124A (zh) *	2006-07-03	2016-11-23	让-保罗·佩罗丹	抗菌剂组合物及其用途
GB0705557D0 (en) *	2007-03-23	2007-05-02	Stead Richard G	A treatment
JP5558458B2 (ja) *	2008-03-20	2014-07-23	タノメド・アクチボラゲット	普通感冒の治療用の医薬の製造における物質の使用
US20110229438A1 (en)	2008-10-09	2011-09-22	Anadys Pharmaceuticals, Inc.	Method of inhibiting hepatitus c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
JP2009215301A (ja) *	2009-04-27	2009-09-24	Morinaga Milk Ind Co Ltd	プロテアーゼ阻害剤
NZ600269A (en) *	2009-05-20	2014-02-28	Dec Int Nz Ltd	Delivery device for treatment of mastitis
JP5306537B2 (ja) *	2010-02-24	2013-10-02	森永乳業株式会社	昆布抽出物を有効成分とする抗菌補助剤、抗菌組成物、及び飲食品
US10640464B2 (en)	2011-01-03	2020-05-05	The William M. Yarbrough Foundation	Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US11279674B2 (en)	2011-01-03	2022-03-22	The William M. Yarbrough Foundation	Isothiocyanate functional surfactant and associated method of use
US8933119B2 (en)	2011-01-03	2015-01-13	The William M. Yarbrough Foundation	Method for treating phytophotodermatitis
US11407713B2 (en)	2011-01-03	2022-08-09	The William M. Yarbrough Foundation	Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10273205B2 (en)	2011-01-03	2019-04-30	The William M. Yarbrough Foundation	Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US10308599B2 (en)	2011-01-03	2019-06-04	The William M. Yarbrough Foundation	Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US9962361B2 (en)	2011-01-03	2018-05-08	The William M. Yarbrough Foundation	Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10647668B2 (en)	2011-01-03	2020-05-12	The William M. Yarbrough Foundation	Isothiocyanate functional surfactant and associated method of use
US8865765B2 (en)	2011-01-12	2014-10-21	The William M. Yarbrough Foundation	Method for treating eczema
US9532969B2 (en)	2011-02-08	2017-01-03	The William M. Yarbrough Foundation	Method for treating psoriasis
US9839621B2 (en)	2012-07-26	2017-12-12	The William M. Yarbrough Foundation	Method for treating bladder cancer
US10441561B2 (en)	2012-07-26	2019-10-15	The William M. Yanbrough Foundation	Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10434082B2 (en)	2012-07-26	2019-10-08	The William M. Yarbrough Foundation	Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US9949943B2 (en)	2012-07-26	2018-04-24	The William M. Yarbrough Foundation	Method for treating neurodegenerative diseases
WO2014018874A1 (en)	2012-07-26	2014-01-30	The William M. Yarbrough Foundation	Method for treating skin cancer
US10080734B2 (en)	2012-07-26	2018-09-25	The William M. Yarbrough Foundation	Method for treating autism and other neurodevelopmental disorders
US10434081B2 (en)	2012-07-26	2019-10-08	The William M. Yarbrough Foundation	Inhibitors of macrophage migration inhibitory factor
US10335387B2 (en)	2012-07-26	2019-07-02	The William M. Yarbrough Foundation	Method for treating infectious diseases with isothiocyanate functional compounds
US20150282489A1 (en)	2012-11-30	2015-10-08	Dsm Ip Assets B.V.	Synergistic fungicidal compositions containing lactoperoxidase system
NZ726323A (en)	2014-04-30	2020-02-28	Matoke Holdings Ltd	Antimicrobial compositions
WO2016059654A1 (en) *	2014-10-16	2016-04-21	Giuseppe Baricco	Use of glucose oxidase for the control, the prevention and the cure of intestinal disorders
GB2540130B (en) *	2015-06-29	2021-04-14	Institute Of Tech Sligo	A composition and a method for controlling bacterial infection
GB201716986D0 (en)	2017-10-16	2017-11-29	Matoke Holdings Ltd	Antimicrobial compositions
EP4309500B1 (en)	2022-07-18	2025-06-04	Acies Bio d.o.o.	Peroxidase based biocontrol agents
US20250332227A1 (en)	2022-07-18	2025-10-30	Acies Bio D.O.O.	Peroxidase based biocontrol agents
GB2635741B (en) *	2023-11-24	2026-03-18	Killian Obriain	Composition and use thereof for the treatment of equine gastric ulcer syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE420793B (sv) *	1976-03-08	1981-11-02	Astra Ewos Ab	Fodermedel innehallande ett antibakteriellt system
US4578265A (en) *	1981-08-13	1986-03-25	Laclede Professional Products, Inc.	Di-enzymatic dentifrice
US4564519A (en) *	1983-06-06	1986-01-14	Laclede Professional Products, Inc.	Di-enzymatic chewable dentifrice
DK501686A (da) *	1986-10-20	1988-04-21	Otto Melchior Poulsen	Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det
SE469004B (sv) *	1989-03-07	1993-04-26	Nobeltech Electronics Ab	Nattkikare
FR2646777B1 (fr) *	1989-05-12	1993-09-03	Bio Serae Lab	Procede de preparation d'un produit particulaire antimicrobien, produit antimicrobien obtenu et applications
GB9002422D0 (en) *	1990-02-03	1990-04-04	Boots Co Plc	Anti-microbial compositions
US5453284A (en) *	1993-01-29	1995-09-26	Pellico; Michael A.	Stabilized enzymatic dentifrice
US5336494A (en) *	1993-01-29	1994-08-09	Pellico Michael A	Pet chewable products with enzymatic coating

1996
- 1996-01-23 SE SE9600233A patent/SE506529C2/sv not_active IP Right Cessation
1997
- 1997-01-22 US US09/117,029 patent/US6149908A/en not_active Expired - Fee Related
- 1997-01-22 EP EP97901880A patent/EP1007086B1/en not_active Expired - Lifetime
- 1997-01-22 WO PCT/SE1997/000098 patent/WO1997026908A1/en not_active Ceased
- 1997-01-22 AU AU15627/97A patent/AU731221B2/en not_active Ceased
- 1997-01-22 CA CA002243708A patent/CA2243708C/en not_active Expired - Fee Related
- 1997-01-22 AT AT97901880T patent/ATE220556T1/de not_active IP Right Cessation
- 1997-01-22 DE DE69714083T patent/DE69714083T2/de not_active Expired - Fee Related
- 1997-01-22 JP JP9526782A patent/JP2000509367A/ja active Pending

Also Published As

Publication number	Publication date
ATE220556T1 (de)	2002-08-15
EP1007086B1 (en)	2002-07-17
WO1997026908A1 (en)	1997-07-31
CA2243708A1 (en)	1997-07-31
SE9600233L (sv)	1997-07-24
DE69714083D1 (de)	2002-08-22
JP2000509367A (ja)	2000-07-25
CA2243708C (en)	2007-04-24
US6149908A (en)	2000-11-21
SE9600233D0 (sv)	1996-01-23
AU1562797A (en)	1997-08-20
DE69714083T2 (de)	2003-03-27
AU731221B2 (en)	2001-03-29
EP1007086A1 (en)	2000-06-14

Legal Events

Date	Code	Title	Description
2010-10-05	NUG	Patent has lapsed

Publication	Publication Date	Title
SE506529C2 (sv)	1997-12-22	Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
RU2385736C2 (ru)	2010-04-10	Композиции, содержащие липазу, протеазу и амилазу, предназначенные для лечения недостаточности поджелудочной железы
US10596235B2 (en)	2020-03-24	Pharmaceutical preparation
NO854391L (no)	1986-05-06	Farmasoeytisk matrise for ibuprofen.
US5260280A (en)	1993-11-09	Bacterial toxin neutralizer
EP0828509A1 (en)	1998-03-18	Composition to improve digestibility and utilisation of nutrients
NO149197B (no)	1983-11-28	Fremgangsmaate for fremstilling av naeringsmidler inneholdende et antibakterielt system
CN1901924B (zh)	2010-04-28	用于抑制细菌定居的方法
RU2104710C1 (ru)	1998-02-20	Фармацевтические бактериоциновые композиции и их применение
JP2002525266A (ja)	2002-08-13	感染性潰瘍又は胃炎に対するタウロリジン及び／又はタウルルタム
JP7554807B2 (ja)	2024-09-20	消化障害の予防および／または処置用の医薬組成物およびそれを製造する方法、並びにそれを含む医薬製品
JPH09241177A (ja)	1997-09-16	腸管保護剤
JP2002265365A (ja)	2002-09-18	好中球機能抑制剤
JP3390613B2 (ja)	2003-03-24	ビフィズス因子の活性増強・安定化剤
JPH11158075A (ja)	1999-06-15	膵機能調節剤
Slomiany et al.	1997	Suppression of Helicobacter pylori urease activity by sucralfate and sulglycotide
RU2149008C1 (ru)	2000-05-20	Способ получения биопрепарата
JPH07179355A (ja)	1995-07-18	ＩｇＧおよびＩｇＭクラスの抗体産生を促進する免疫賦活剤
JP2761815B2 (ja)	1998-06-04	酪酸菌の液剤
US5436004A (en)	1995-07-25	Administration of cholesterol reductase to humans
JP2003073278A (ja)	2003-03-12	抗ヘリコバクターピロリ剤
JP3212364B2 (ja)	2001-09-25	新規なローヤルゼリー配合物
JPH10130164A (ja)	1998-05-19	胃腸障害予防及び／又は治療剤
RU2325166C1 (ru)	2008-05-27	Фармацевтическая композиция антибиотиков и лактулозы для профилактики энтеральных дисбиозов в процессе антибиотикотерапии
EP1043022B1 (en)	2007-07-11	Sodium ion absorption inhibitors and sodium ion excretion accelerators as preventive and therapeutic agents for diseases resulting from excessive intake of common salt